Compare CSW & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSW | TMDX |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | N/A | 2019 |
| Metric | CSW | TMDX |
|---|---|---|
| Price | $307.24 | $123.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $309.25 | $144.25 |
| AVG Volume (30 Days) | 174.8K | ★ 724.8K |
| Earning Date | 01-29-2026 | 10-29-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | 15.78 | ★ 170.70 |
| EPS | ★ 8.52 | 2.54 |
| Revenue | ★ $964,795,000.00 | $566,354,000.00 |
| Revenue This Year | $25.92 | $38.81 |
| Revenue Next Year | $16.37 | $20.49 |
| P/E Ratio | ★ $36.05 | $48.97 |
| Revenue Growth | 14.87 | ★ 41.20 |
| 52 Week Low | $230.45 | $55.00 |
| 52 Week High | $401.02 | $156.00 |
| Indicator | CSW | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 43.84 |
| Support Level | $301.77 | $120.82 |
| Resistance Level | $317.51 | $133.29 |
| Average True Range (ATR) | 10.69 | 5.52 |
| MACD | -1.99 | -0.91 |
| Stochastic Oscillator | 52.24 | 19.55 |
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.